Figure 3.
Figure 3. CD85j and KIR expression in lymphocytes from HCMV-positive individuals. PBLs from HCMV-positive (n = 11) and HCMV-negative donors (n = 13) were stained with anti-CD3 and CD56-specific mAbs in combination with either anti-CD85j, KIR3DL1, KIR2DL1/S1, or KIR2DL2/S2/L3 mAbs (Protocol 2; see “Immunofluorescence and flow cytometry analysis”). Samples were analyzed by flow cytometry, and the proportions of T (CD3+) and NK (CD3-CD56+) cells expressing the different NKRs were calculated (mean ± SEM). According to their KIR genotype, donors lacking KIR2DL1/S1 or KIR2DL2/S2/L3 genes were excluded. Statistical analysis was carried out as described in “Patients, materials, and methods”; *P < .05; **P < .01.

CD85j and KIR expression in lymphocytes from HCMV-positive individuals. PBLs from HCMV-positive (n = 11) and HCMV-negative donors (n = 13) were stained with anti-CD3 and CD56-specific mAbs in combination with either anti-CD85j, KIR3DL1, KIR2DL1/S1, or KIR2DL2/S2/L3 mAbs (Protocol 2; see “Immunofluorescence and flow cytometry analysis”). Samples were analyzed by flow cytometry, and the proportions of T (CD3+) and NK (CD3-CD56+) cells expressing the different NKRs were calculated (mean ± SEM). According to their KIR genotype, donors lacking KIR2DL1/S1 or KIR2DL2/S2/L3 genes were excluded. Statistical analysis was carried out as described in “Patients, materials, and methods”; *P < .05; **P < .01.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal